To arrange an interview, please contact the NHLBI Communications Office at 301-496-4236 or email@example.com.
Jacques Rossouw, MB.ChB., F.C.P. (S.A.), M.D., is chief of the Women’s Health Initiative (WHI) Branch in the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH).
Dr. Rossouw oversees the WHI, which was established by the NIH in 1991 to address the most common causes of death, disability and impaired quality of life in postmenopausal women. The WHI is comprised of a set of clinical trials and observational studies involving over 161,000 postmenopausal women investigating risk factors and testing prevention strategies for heart disease, cancers of the breast and the large bowel, and fractures due to osteoporosis in women. The WHI is one of the largest U.S. prevention studies of its kind.
Prior to joining the NHLBI in 1989, Dr. Rossouw served as the director of the National Research Institute for Nutritional Diseases of the South African Medical Research Council, where he was responsible for launching the Coronary Risk Factor Study (CORIS), a community prevention trial.
Dr. Rossouw graduated from the University of Cape Town in South Africa, where he studied internal medicine and hepatology.
Dr. Rossouw is the author or coauthor of more than 150 articles and book chapters on a variety of topics, including postmenopausal hormone therapy and cardiovascular disease, lipids, nutrition, and community intervention studies.
Areas of expertise: examination of epidemiologic and clinical trial data on postmenopausal hormone therapy, lipids and other biomarkers, and coronary heart disease
March 6, 2012
Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy
coauthored by Jacques Rossouw, MB.ChB., F.C.P. (S.A.), M.D., Division of Cardiovascular Sciences
We report the first prospective study of the associations of acquired APC resistance and of TFPI levels with stroke, and we examine whether PHT-induced changes in these factors are associated with stroke risk in the WHI trials. We also examine associations with major subgroups of stroke.
February 15, 2010
WHI Study Data Confirm Short-Term Heart Disease Risks of Combination Hormone Therapy for Postmenopausal Women
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women.